Equities analysts predict that Aptevo Therapeutics Inc. (NASDAQ:APVO) will announce sales of $3.40 million for the current quarter, Zacks reports. Two analysts have issued estimates for Aptevo Therapeutics’ earnings, with estimates ranging from $3.30 million to $3.50 million. The company is scheduled to report its next earnings results on Friday, February 11th.
On average, analysts expect that Aptevo Therapeutics will report full year sales of $12.03 million for the current financial year, with estimates ranging from $11.93 million to $12.13 million. For the next fiscal year, analysts anticipate that the firm will post sales of $15.90 million, with estimates ranging from $13.80 million to $18.00 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that follow Aptevo Therapeutics.
A number of equities analysts have recently commented on the company. Zacks Investment Research lowered Aptevo Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 19th. Roth Capital dropped their price objective on Aptevo Therapeutics from $50.00 to $36.00 and set a “buy” rating on the stock in a research note on Monday, November 15th.
In related news, major shareholder Kevin C. Tang sold 369,533 shares of the business’s stock in a transaction dated Thursday, November 18th. The stock was sold at an average price of $8.34, for a total transaction of $3,081,905.22. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Kevin C. Tang sold 255,331 shares of the business’s stock in a transaction dated Monday, November 22nd. The shares were sold at an average price of $7.03, for a total value of $1,794,976.93. The disclosure for this sale can be found here. Insiders own 10.88% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the company. Moors & Cabot Inc. bought a new stake in shares of Aptevo Therapeutics in the 3rd quarter valued at approximately $3,729,000. Kennedy Capital Management Inc. bought a new stake in shares of Aptevo Therapeutics in the 2nd quarter valued at approximately $4,217,000. Vanguard Group Inc. grew its stake in shares of Aptevo Therapeutics by 2.9% in the 2nd quarter. Vanguard Group Inc. now owns 134,760 shares of the biotechnology company’s stock valued at $3,022,000 after purchasing an additional 3,830 shares during the period. BlackRock Inc. boosted its holdings in shares of Aptevo Therapeutics by 1.9% in the 3rd quarter. BlackRock Inc. now owns 55,394 shares of the biotechnology company’s stock worth $856,000 after acquiring an additional 1,010 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Aptevo Therapeutics by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 39,924 shares of the biotechnology company’s stock worth $616,000 after acquiring an additional 1,007 shares in the last quarter. Institutional investors own 96.53% of the company’s stock.
About Aptevo Therapeutics
Aptevo Therapeutics, Inc is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology.
Featured Article: How Do You Make Money With Penny Stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.